Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2019-08-15 Earnings Release
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S.
Earnings Release Classification · 98% confidence The document is titled 'Company announcement – No. 25 / 2019' and explicitly states that the company 'today announced financial results for the first half of 2019.' It provides key financial figures (Revenue, Net operating expenses, Net operating result) and business highlights for the period ending June 30, 2019. This structure—a summary announcement of period-specific financial results—aligns perfectly with the definition of an Earnings Release (ER). Although it contains extensive pipeline updates, the primary purpose of this specific announcement is the release of H1 2019 financial performance highlights. It is not the comprehensive 'Interim Report' (IR) itself, but the initial release of the results. H1 2019
2019-08-15 English
Earnings Release 2019
Earnings Release Classification · 100% confidence The document explicitly states it announces 'financial results for the first half of 2019' and provides detailed financial figures (Revenue, Net operating expenses, Net operating result) and business highlights for that period. This content structure—a summary of financial performance for a period shorter than a year (H1 2019)—is characteristic of an Interim/Quarterly Report. It is comprehensive enough to be an 'IR' rather than just a brief 'ER' (Earnings Release) or an 'RPA' (announcement of a report). The presence of a conference call announcement further supports this being the primary results document. H1 2019
2019-08-15 English
Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S.
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2019 (H1 2019) for Zealand Pharma. It includes detailed financial results (revenue, operating expenses, net operating result, cash position), business highlights, pipeline updates, and financial guidance. It is not a mere announcement of a report (RPA) because it contains substantive financial data and analysis. It is not a full 10-K as it covers only a six-month period. Therefore, it is classified as an Interim/Quarterly Report. H1 2019
2019-08-15 English
Zealand Pharma announces change in corporate management
Board/Management Information Classification · 100% confidence The document is a company announcement titled 'Zealand Pharma announces change in corporate management'. It details the departure of an Executive Vice President and Chief Scientific Officer and the appointment of an interim lead. This falls directly under the definition of Board/Management Information (MANG).
2019-07-29 English
Board/Management Information 2019
Board/Management Information Classification · 100% confidence The document is titled "Zealand Pharma announces change in corporate management" and details the departure of an Executive Vice President and Chief Scientific Officer, including quotes from the departing executive and the CEO. This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information' (Code: MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3731 chars), but the core content is the announcement itself, not just a notice that a report is attached, making MANG a better fit than RPA or RNS.
2019-07-29 English
Total number of shares and voting rights in Zealand Pharma at June 30, 2019
Share Issue/Capital Change Classification · 95% confidence The document is a formal company announcement regarding a change in the total number of shares and voting rights following an increase in share capital due to the exercise of employee warrants. This type of disclosure is specifically related to changes in share capital structure and issuance, which falls under the 'Share Issue/Capital Change' category.
2019-06-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.